<DOC>
	<DOCNO>NCT00528242</DOCNO>
	<brief_summary>To investigate severity secondary Raynaud 's disease-related attack 14 day 2101 dose period .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacodynamic Profile Oral 2101 Secondary Raynaud 's Disease</brief_title>
	<detailed_description>1 . Number cumulative duration Raynaud 's attack . 2 . Adverse event change vital sign . 3 . SLx-2101 pharmacokinetic parameter derive dose Day 1 Day maximum plasma concentration ( Cmax ) , area plasma concentration-time curve ( AUC0-4 ) , time Cmax ( tmax ) , accumulation ratio</detailed_description>
	<mesh_term>Raynaud Disease</mesh_term>
	<criteria>male female age 18 65 y.o . BMI Body weight within body mass index range 17 30 kg/m2 ( inclusive ) . Hypersensitivity active substance SLx2101or excipients . Past present disease judge Investigator potential interfere study procedure , compromise safety , affect pharmacokinetic pharmacodynamic evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>